ImmuCell Corporation Accrued Liabilities, Current
ImmuCell Corporation (ICCC) had Accrued Liabilities, Current of $367.23 thousand as of 2014-09-30, per its 10-Q filed 2014-11-12.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2014-11-12
- 2014-09-30: Accrued Liabilities, Current $367.23K.
- 2014-06-30: Accrued Liabilities, Current $458.62K.
- 2014-03-31: Accrued Liabilities, Current $282.99K.
- 2013-12-31: Accrued Liabilities, Current $293.08K.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2014-09-30 | $367.23K 10-Q · filed 2014-11-12 |
| 2014-06-30 | $458.62K 10-Q · filed 2014-08-13 |
| 2014-03-31 | $282.99K 10-Q · filed 2014-05-14 |
| 2013-12-31 | $293.08K 10-Q · filed 2014-11-12 |
| 2013-09-30 | $212.08K 10-Q · filed 2013-11-13 |
| 2013-06-30 | $285.78K 10-Q · filed 2013-08-13 |
| 2013-03-31 | $232.60K 10-Q · filed 2013-05-14 |
| 2012-12-31 | $255.57K 10-K · filed 2014-03-26 |
| 2012-09-30 | $205.28K 10-Q · filed 2012-11-13 |
| 2012-06-30 | $229.52K 10-Q/A · filed 2012-09-07 |
| 2012-03-31 | $239.00K 10-Q · filed 2012-05-14 |
| 2011-12-31 | $303.90K 10-K · filed 2013-03-28 |
| 2011-09-30 | $331.40K 10-Q · filed 2011-11-14 |
| 2011-06-30 | $652.88K 10-Q · filed 2011-08-15 |
| 2010-12-31 | $372.05K 10-K · filed 2012-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |